Journal of Clinical Medicine,
Journal Year:
2024,
Volume and Issue:
13(14), P. 4081 - 4081
Published: July 12, 2024
Background:
The
COVID-19
pandemic
caused
an
unprecedented
number
of
patients
requiring
veno-venous
extracorporeal
membrane
oxygenation
(VV
ECMO)
therapy.
Clinical
polyuria
was
observed
at
our
ECMO
center
during
the
pandemic.
This
study
aims
to
investigate
incidence,
potential
causes,
and
implications
in
undergoing
VV
Methods:
Here,
68
SARS-CoV-2
positive
receiving
were
stratified
into
following
two
groups:
(PU),
characterized
by
average
urine
output
≥3000
mL/day
within
seven
days
initiation,
non-polyuria
(NPU),
defined
<3000
mL/day.
Polyuria
occurred
51.5%
(n
=
35)
after
initiation.
No
significant
difference
mortality
between
PU
NPU
groups
(60.0%
vs.
60.6%).
Differences
found
fluid
intake
(p
<
0.01)
balance
24
h
0.01),
creatinine
plasma
osmolality
lactate
urea
sodium
levels
groups.
Plasma
increased
initiation
observation
period.
Results:
Diuresis
treatment,
while
not
affected
polyuria.
Conclusions:
does
appear
impact
mortality.
Further
investigations
are
warranted
elucidate
its
underlying
mechanisms
clinical
context
therapy
management.
Journal of Critical Care,
Journal Year:
2024,
Volume and Issue:
82, P. 154802 - 154802
Published: April 6, 2024
The
health
and
economic
consequences
of
artificial
intelligence
(AI)
systems
for
mechanically
ventilated
intensive
care
unit
patients
often
remain
unstudied.
Early
technology
assessments
(HTA)
can
examine
the
potential
impact
AI
by
using
available
data
simulations.
Therefore,
we
developed
a
generic
health-economic
model
suitable
early
HTA
patients.
Pharmaceuticals,
Journal Year:
2022,
Volume and Issue:
15(12), P. 1574 - 1574
Published: Dec. 16, 2022
Since
the
beginning
of
COVID-19
pandemic,
clinical,
radiological,
and
histopathological
studies
have
provided
evidence
that
organizing
pneumonia
is
a
possible
consequence
SARS-CoV2
infection.
This
post-COVID-19
(PCOP)
causes
persisting
dyspnea,
impaired
pulmonary
function,
produces
radiological
abnormalities
for
at
least
5
weeks
after
onset
symptoms.
While
most
patients
with
PCOP
recover
within
year
acute
COVID-19,
5-25%
cases
need
specialized
treatment.
However,
despite
substantial
resources
allocated
worldwide
to
finding
solution
this
problem,
there
are
no
approved
treatments
PCOP.
Oral
corticosteroids
produce
therapeutic
response
in
majority
such
patients,
but
their
application
limited
by
anticipated
high-relapse
frequency
risk
severe
adverse
effects.
Herein,
we
conduct
systematic
comparison
epidemiology,
pathogenesis,
clinical
presentation
pneumonias
caused
as
well
other
viral
infections.
We
also
use
efficacy
postinfection
OPs
(PIOPs)
predict
treatment
Finally,
discuss
potential
candidate
anti-inflammatory
antifibrotic
therapy
based
on
analysis
latest
trials
data.
Journal of Inflammation,
Journal Year:
2023,
Volume and Issue:
20(1)
Published: March 20, 2023
Abstract
The
severe
acute
respiratory
syndrome-coronavirus-2
(SARS-CoV-2)
infection
can
be
asymptomatic
or
cause
a
disease
(COVID-19)
characterized
by
different
levels
of
severity.
main
COVID-19
and
death
is
represented
(or
on
chronic)
failure
distress
syndrome
(ARDS),
often
requiring
hospital
admission
ventilator
support.
molecular
pathogenesis
COVID-19-related
ARDS
(by
now
termed
c-ARDS)
still
poorly
understood.
In
this
review
we
will
discuss
the
genetic
susceptibility
to
COVID-19,
local
systemic
biomarkers
correlated
with
c-ARDS
therapeutic
options
that
target
cell
signalling
pathways
c-ARDS.
Health Economics Review,
Journal Year:
2024,
Volume and Issue:
14(1)
Published: Jan. 16, 2024
While
COVID-19
hospitalization
costs
are
essential
for
policymakers
to
make
informed
health
care
resource
decisions,
little
is
known
about
these
in
western
Europe.
The
aim
of
the
current
study
analyze
a
German
setting,
track
development
over
time
and
daily
costs.
PLoS ONE,
Journal Year:
2025,
Volume and Issue:
20(2), P. e0314164 - e0314164
Published: Feb. 7, 2025
Aim
The
aim
of
this
study
is
to
quantify
the
effectiveness
and
cost-effectiveness
outpatient
inpatient
sectors
(specifically
intensive
care
units,
ICUs)
local
health
departments
in
managing
first
three
waves
COVID-19
pandemic
Germany.
Methods
analysis
based
on
a
modelling
approach
using
secondary
data.
each
sector
was
measured
by
determining
reduction
case
fatality
rate
(CFR)
patients
May
7,
2021.
A
counterfactual
scenario
assuming
absence
used
their
effectiveness.
Direct
medical
costs
for
were
calculated
from
statutory
insurance
perspective,
utilizing
reimbursement
rates
both
sectors.
Incremental
ratios
(ICERs)
determined,
representing
per
death
avoided.
Results
ICUs
achieved
greatest
CFR
during
(1.9%).
followed
with
1.4%,
contributed
0.3%
decrease
CFR.
In
terms
spending,
had
highest
expenditures
among
sectors,
resulting
an
ICER
€59,055
On
other
hand,
costlier
but
less
effective
than
sector.
remained
consistent
across
various
input
assumptions.
Conclusion
During
Germany,
(ICUs)
made
largest
contribution
preventing
deaths
while
also
incurring
costs.
Open Forum Infectious Diseases,
Journal Year:
2025,
Volume and Issue:
12(4)
Published: March 26, 2025
Abstract
Background
To
prevent
severe
disease,
nirmatrelvir/ritonavir
(nirmatrelvir/r)
is
administered
to
individuals
infected
with
SARS-CoV-2
who
are
at
high
risk,
and
it
currently
priced
approximately
$1375
in
the
Netherlands.
We
aim
evaluate
health
outcomes
cost-effectiveness
of
nirmatrelvir/r
among
patients
risk
disease.
Methods
used
a
decision-analytic
model
parameterized
clinical
care
utilization
data
from
were
between
September
2021
November
2023.
assumed
baseline
event
rates
1%
for
hospitalization
0.05%
intensive
unit
admission.
Nirmatrelvir/r-related
factors
varied.
Costs
collected
third-party
payer’s
perspective,
threshold
was
<$88
000
per
quality-adjusted
life-year
gained.
Sensitivity
analyses
performed
account
uncertainties.
Results
This
study
included
949
SARS-CoV-2.
The
sample
had
median
age
65
years
(IQR,
53–75),
416
(44%)
participants
female.
Comorbidities
obesity
(25%),
hematologic
malignancy
(21%),
solid
organ/stem
cell
transplantation
(17%),
immunosuppressive
medication
use
(47%).
With
an
low
effectiveness,
could
reduce
hospitalizations
deaths
(relative
reduction,
21%
44%,
respectively).
relative
reductions
89%
90%
calculated
deaths.
Higher
hospital
admission
positively
influenced
thresholds.
Nirmatrelvir/r
cost-effectively
<$512
effectiveness
<$1071
effectiveness.
Conclusions
current
hospitalization,
has
potential,
not
only
COVID-19
but
do
so
drug
price
reduction
22%
63%.
These
findings
relevant
policy
makers
physicians
emphasize
importance
reevaluating
pricing.
Clinical
Trials
Registration
NCT05195060
(ClinicalTrials.gov).
Clinical Nutrition ESPEN,
Journal Year:
2023,
Volume and Issue:
56, P. 9 - 12
Published: April 26, 2023
This
study
aimed
to
evaluate
the
ability
of
urea-to-albumin
ratio
(UAR)
predict
mortality
in
critically
ill
coronavirus
disease
2019
(COVID-19)
patients.This
retrospective
included
adult
patients
admitted
with
COVID-19
at
two
intensive
care
units
(ICUs)
University
Hospital.
Serum
urea
and
albumin
concentrations
ICU
admission
were
used
calculate
UAR.
All
followed
up
during
hospitalization,
rate
was
recorded.Two
hundred
eleven
evaluated.
The
mean
age
57.8
±
15.5
years,
54%
male.
Approximately
84.4%
considered
be
nutritional
risk
by
NRS
2002,
median
UAR
18.3
(10.5-34.8).
length
stay
10
(6-16)
days,
38.4%
required
dialysis,
64.9%
died.
Age,
male
sex,
need
hemodialysis,
lactate
level,
inflammatory
parameters
associated
higher
mortality.
Patients
non-survivors
had
a
(23.7
[13.6-41.8]
vs.
10.9
[8.5-16.8];
p
<
0.001).
cutoff
point
best
performance
ROC
curve
for
predicting
≥12.17
(AUC:
0.7201;
CI
95%:
0.656-0.784).
Additionally,
2.00-fold
group
(HR:
2.00
CI:
1.274-3.149;
=
0.003)
remained
significant
after
adjusted
analyzes
(models
1
2).Our
data
suggest
that
increased
patients.
Talanta,
Journal Year:
2023,
Volume and Issue:
268, P. 125295 - 125295
Published: Oct. 9, 2023
The
COVID-19
pandemic
challenged
the
management
of
technical
and
human
resources
in
intensive
care
units
(ICU)
across
world.
Several
long-term
predictors
for
disease
progression
have
been
discovered.
However,
to
support
short-term
planning
medication
that
can
be
translated
future
pandemics
are
still
missing.
A
workflow
was
established
identify
a
predictor
acute
phase
patients
clinical
decision-making.
Thirty-two
with
SARS-CoV-2
infection
were
recruited
on
admission
ICU
data
collected.
During
their
hospitalization,
plasma
samples
acquired
from
each
patient
multiple
occasions,
excepting
one
which
only
time
point
possible,
proteome
(Inflammation,
Immune
Response
Organ
Damage
panels
Olink®
Target
96),
metabolome
lipidome
(flow
injection
analysis
liquid
chromatography-mass
spectrometry)
analyzed
sample.
Patient
visits
grouped
according
changes
severity
based
respiratory
organ
function,
evaluated
using
combination
statistical
machine
learning.
resulting
this
multi-omics
approach
compared
assessment
progression.
Furthermore,
potential
markers
baseline
levels
50
healthy
subjects
no
known
or
other
viral
infections.
total
124
parameters,
271
proteins
782
unique
metabolites
lipids
assessed.
dimensionality
dataset
reduced,
selecting
47
1177
parameters
available
following
down-selection,
build
learning
model.
Subsequently,
two
(C–C
motif
chemokine
7
(CCL7)
carbonic
anhydrase
14
(CA14))
lipid
(hexosylceramide
18:2;
O2/20:0)
linked
studied
Thus,
delivering
prognosis
an
upcoming
worsening
patient's
condition
up
five
days
advance
reasonable
accuracy
(79
%
three
prior
event,
84
four
event)
found.
Interestingly,
predictor's
performance
complementary
clinicians'
capabilities
foresee
patient.
This
study
presents
omics-based
biomarkers
decision-making
resource
ICU.
successfully
applied
develop
aggravation
symptoms.
methods
adapted
small
cohort
studies.
Arquivos Brasileiros de Cardiologia,
Journal Year:
2024,
Volume and Issue:
121(3)
Published: Jan. 1, 2024
Resumo
Fundamento:
A
doença
por
coronavírus
2019
(COVID-19)
está
associada
à
hipercoagulabilidade.
Permanece
incerto
se
a
anticoagulação
contínua
para
fibrilação
atrial
(FA)
em
pacientes
que
posteriormente
contraem
COVID-19
melhora
os
desfechos
clínicos.
Objetivos:
Comparar
oral
crônica
com
ausência
de
prévia
FA
contraíram
uma
infecção
relação
aos
mortalidade
todas
as
causas,
COVID-19,
admissão
unidade
terapia
intensiva
(UTI)
e
hospitalização.
Métodos:
Buscamos
sistematicamente
no
PubMed,
Embase
Cochrane
Library
estudos
elegíveis
desde
o
início
até
dezembro
2022.
Incluímos
compararam
sem
FA.
Foram
agrupadas
razões
risco
(RR)
intervalos
confiança
(IC)
95%
meio
um
modelo
efeitos
aleatórios.
O
nível
significância
foi
estabelecido
p
<
0,05.
As
avaliações
da
qualidade
do
viés
foram
realizadas
acordo
recomendações
Cochrane.
Resultados:
identificados
10
abrangendo
1.177.858
FA,
dos
quais
893.772
(75,9%)
estavam
Em
reduziu
significativamente
causas
(RR
0,75;
IC
0,57
0,99;
=
0,048;
I2
89%)
relacionada
0,76;
0,72
0,79;
0,001;
0%)
quando
comparada
prévia.
contrapartida,
não
houve
diferença
entre
grupos
hospitalização
1,08;
0,82
1,41;
0,587;
95%)
ou
internação
UTI
0,86;
0,68
1,09;
0,216;
69%).
Conclusões:
Nesta
metanálise,
taxas
mais
baixas
comparação
anterior.